Oncolytics Biotech (ONCY) Posts Wider Q4 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Oncolytics Biotech (ONCY) Posts Wider Q4 Loss

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

March 3, 2022 4:01 PM EST

Randomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022

Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker a key finding for de-risking a phase 3 registrational breast cancer study

Interim safety updates from clinical trials in triple-negative breast and gastrointestinal cancers further demonstrate the favorable safety profile of pelareorep-checkpoint inhibitor combinations

Strong financial position with approximately $41.3 million and cash runway through key milestones and into 2023

Management hosting conference call and webcast today at 5:00 p.m.... More